bluebird bio (BLUE) Posts Wider-than-Expected Q3 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
bluebird bio (BLUE) Post-ASH Abstract Sell-Off an 'Overreaction', Oppenheimer Says
November 5, 2015 11:00 AM ESTOppenheimer analyst Wendy Lam weighed in on bluebird bio (NASDAQ: BLUE), saying the Post-ASH abstract sell-off is overdone.
Lam commented, "BLUE published six ASH abstracts this morning, three of which were focused on LentiGlobin in beta-thalassemia and sickle cell disease. Key updates disclosed in the abstracts include new data from additional patients treated in the Northstar and HBG-205... More
bluebird bio (BLUE) Plunges 14% in Early Trade Following ASH Update
November 5, 2015 8:20 AM ESTbluebird bio (NASDAQ: BLUE) is plunging 13.6% in pre-open trading following an update at ASH.
From the company's press release this morning:
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies, announced that data from its ongoing clinical... More
bluebird bio (BLUE) Bullish View Reiterate at Post Q3 and Ahead of ASH Abstract Data -Oppenheimer
November 5, 2015 6:38 AM ESTOppenheimer analyst Wendy Lam reiterated an Outperform rating and $162 price target on bluebird bio (NASDAQ: BLUE) following Q3 results.
Lam commented, "BLUE reported 3Q15 loss per share of ($1.18) and ended the quarter with $901.7M in cash, cash equivalents, and marketable securities; we have updated our... More
